Alumis’ (ALMS) Neutral Rating Reiterated at HC Wainwright

by · The Markets Daily

Alumis (NASDAQ:ALMS – Get Free Report)‘s stock had its “neutral” rating reaffirmed by research analysts at HC Wainwright in a research note issued to investors on Monday,Benzinga reports. They currently have a $25.00 price objective on the stock. HC Wainwright’s price objective suggests a potential downside of 11.50% from the company’s previous close.

ALMS has been the topic of a number of other reports. Chardan Capital raised their price target on shares of Alumis from $38.00 to $40.00 and gave the stock a “buy” rating in a research report on Tuesday, May 19th. Citigroup reissued a “buy” rating on shares of Alumis in a report on Tuesday, May 19th. Wall Street Zen lowered shares of Alumis from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Wells Fargo & Company raised their target price on shares of Alumis from $49.00 to $51.00 and gave the stock an “overweight” rating in a report on Friday, May 15th. Finally, Guggenheim lifted their price target on shares of Alumis from $32.00 to $34.00 and gave the company a “buy” rating in a research report on Friday, May 15th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $40.30.

Read Our Latest Analysis on ALMS

Alumis Price Performance

ALMS stock opened at $28.25 on Monday. Alumis has a fifty-two week low of $3.76 and a fifty-two week high of $31.35. The stock has a market capitalization of $3.60 billion, a price-to-earnings ratio of -14.27 and a beta of -0.73. The business’s fifty day moving average price is $25.08 and its two-hundred day moving average price is $25.15.

Alumis (NASDAQ:ALMS – Get Free Report) last announced its earnings results on Thursday, May 14th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.01). Alumis had a negative net margin of 2,825.70% and a negative return on equity of 88.79%. The business had revenue of $1.74 million during the quarter, compared to the consensus estimate of $2.10 million. Research analysts expect that Alumis will post -2.87 EPS for the current year.

Insider Activity at Alumis

In related news, insider Sanam Pangali sold 5,000 shares of the firm’s stock in a transaction on Monday, July 6th. The stock was sold at an average price of $28.00, for a total value of $140,000.00. Following the transaction, the insider owned 11,111 shares in the company, valued at approximately $311,108. This trade represents a 31.03% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 33.70% of the company’s stock.

Institutional Investors Weigh In On Alumis

Large investors have recently bought and sold shares of the company. Ieq Capital LLC increased its holdings in Alumis by 4.1% in the 4th quarter. Ieq Capital LLC now owns 17,421 shares of the company’s stock valued at $170,000 after buying an additional 690 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Alumis by 26.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,724 shares of the company’s stock worth $46,000 after acquiring an additional 979 shares in the last quarter. Strs Ohio boosted its position in shares of Alumis by 300.0% during the 1st quarter. Strs Ohio now owns 2,000 shares of the company’s stock worth $44,000 after acquiring an additional 1,500 shares in the last quarter. ProShare Advisors LLC increased its stake in Alumis by 12.4% in the fourth quarter. ProShare Advisors LLC now owns 14,627 shares of the company’s stock valued at $143,000 after acquiring an additional 1,618 shares during the last quarter. Finally, KBC Group NV bought a new position in Alumis in the first quarter valued at approximately $42,000.

Alumis Company Profile

(Get Free Report)

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.

Further Reading